TFIID and MYB Share a Therapeutic Handshake in AML

Charles C Bell; Mark A Dawson

doi:10.1016/j.ccell.2017.12.008

TFIID and MYB Share a Therapeutic Handshake in AML

Cancer Cell. 2018 Jan 8;33(1):1-3. doi: 10.1016/j.ccell.2017.12.008.

Authors

Charles C Bell¹, Mark A Dawson²

Affiliations

¹ Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3052, Australia.
² Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3052, Australia; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. Electronic address: mark.dawson@petermac.org.

PMID: 29316424
DOI: 10.1016/j.ccell.2017.12.008

Abstract

Selectively disrupting oncogenic transcription factors in cancer remains an elusive ambition of targeted therapeutics. In this issue of Cancer Cell, Xu et al. provide an elegant proof-of-concept study demonstrating that interaction between MYB and the general transcriptional coactivator TFIID can be specifically disrupted to mediate a therapeutic effect in AML.

Publication types

Comment

MeSH terms

Humans
Leukemia, Myeloid, Acute
Transcription Factor TFIID / genetics*
Transcription Factors*
Transcription, Genetic

Substances

Transcription Factor TFIID
Transcription Factors